Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
作者信息
Swords Ronan T, Greenberg Peter L, Wei Andrew H, Durrant Simon, Advani Anjali S, Hertzberg Mark S, Lewis Ian D, Rivera Gabriel, Gratzinger Dita, Fan Alice C, Felsher Dean W, Cortes Jorge E, Watts Justin M, Yarranton Geoff T, Walling Jackie M, Lancet Jeffrey E
机构信息
Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States.
Stanford Cancer Institute, Stanford, CA, United States.
出版信息
Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30.
Abstract
摘要
Zotero 插件